Major Players - HER-2 Negative Breast Cancer Industry

 

The rising burden of breast cancer around the world is one of the main reasons anticipated to boost the growth of the worldwide HER-2 negative breast cancer market over the forecast period. For instance, according to the American Cancer Society, more than 15% to 20% of breast tumors have higher levels of the protein known as HER2.  The increase in clinical trials is another element fueling the expansion of the global HER-2 negative breast cancer market.

The market for  HER-2 Negative Breast Cancer was estimated to be worth US$12,647.0 million in 2022 and is anticipated to grow at a CAGR of 10.1% from 2023 to 2030 to reach US$27,201.2 million.

Prominent Players in the HER-2 Negative Breast Cancer Industry:

Pfizer Inc.:

1. Pfizer Inc. is a pharmaceutical and biotechnology company based in America. It was founded in the year 1849. Pfizer manufactures and produces vaccines and medicine related to oncology, neurology, cardiology, and immunology. The corporation has produced various products that yield more than US$1 billion in annual revenue. The company ranked 64^th on the Fortune 500 and 49^th on the Forbes Global 2000. The headquarters are located in New York City, U.S. and the products manufactured are sold worldwide. The company was founded by Charles Pfizer and Charles F. Erhart.  In 2022, the company acquired Arena Pharmaceuticals for US$ 6.7 Billion. In October 2022, Pfizer completed the acquisition Biohaven Pharma for US$ 11.6 Billion.

Novartis AG:

2. Founded in 1996. Headquarters for operations in Basel, Switzerland.  Innovative Medicines and Sandoz are two of Novartis' business divisions that design and produce medical products. company Innovative pharmaceuticals sector, which includes international business franchises in oncology, ophthalmology, neurology, immunology, respiratory, cardio-metabolic, and established pharmaceuticals, accounts for the vast bulk of company revenue. The corporation sells its goods all around the world, with the United States accounting for over one-third of total sales. Novartis successfully acquires The Medicines Company, adding the investigational cholesterol-lowering drug inclisiran, which may be a first-in-class treatment.

Merck & Co. Inc.:

3. Founded in 1891. Headquarters in the United States.  Merck produces pharmaceuticals to treat a variety of diseases in a number of therapeutic fields, such as cancer, infections, and cardiometabolic disease. The company's immuno-oncology platform is expanding as a significant contributor to overall sales in the cancer market. The corporation also operates a sizable vaccination division that offers vaccines for shingles, hepatitis B, paediatric illnesses, and HPV. Merck also offers medicines for animal health. Geographically speaking, the United States accounts for just under half of the company's sales. The purchase of Acceleron Pharma Inc. (Nasdaq: XLRN) by Merck (NYSE: MRK), also known as MSD outside of North America and Canada, has been successfully completed, the company stated today.

GSK PLC:

4. Located in England, in the United Kingdom. Established on December 27, 2000. According to overall sales, GSK is one of the biggest corporations in the pharmaceutical sector. The corporation exercises its influence in a number of therapeutic areas, including vaccines, cancer, antiviral, and respiratory treatments. GSK employs collaborative ventures to increase its market share in niche sectors like the HIV market. GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) declared today that they have reached an agreement under which GSK will acquire BELLUS, a late-stage biopharmaceutical company based in Canada that is working to improve the lives of patients with refractory chronic cough (RCC), for US$14.75 per share of common stock in cash, or roughly US$2.0 billion (£1.6 billion) in total equity value.

AstraZeneca:

5. Founded in 1913. Located in England, in the United Kingdom.  AstraZeneca was created in 1999 through the union of the Swedish company Astra with the British company Zeneca Group. The company sells branded medications in a number of important therapeutic categories, including those for gastrointestinal, diabetic, cardiovascular, respiratory, cancer, immunology, and rare disorders. Nearly one-third of its sales originate from the United States, which is one of the largest foreign markets. CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical firm, was successfully acquired by AstraZeneca in 2023. CinCor is dedicated to developing cutting-edge therapies for resistant and uncontrolled hypertension as well as chronic kidney disease.

Eli Lilly and Company:

6. Eli Lilly is a pharmaceutical company with a focus on immunology, cancer, cardiometabolic disease, and neuroscience. Verzenio for cancer, Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes, Taltz, and Olumiant for immunology are some of Lilly's most important pharmaceuticals. Built in 1875. U.S. headquarters are in Indianapolis.

Bristol-Myers Squibb Company (Celgene Corporation):

7. Bristol-Myers Squibb finds, creates, and sells medications for a range of therapeutic areas, including immunological, cancer, and cardiovascular illnesses. Founded 1887. American headquarters in New York. Turning Point Therapeutics is now part of Bristol Myers Squibb, broadening its portfolio of precision oncology products.

*Definition: 

HER2-negative negative breast cancer means that the cancerous cells do not contain high levels of the protein HER2.